107 related articles for article (PubMed ID: 36059654)
1. Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study.
Liu Y; Ge Q; Xu S; Li K; Liu Y
Front Oncol; 2022; 12():942678. PubMed ID: 36059654
[TBL] [Abstract][Full Text] [Related]
2. Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China.
Zhang X; Zeng L; Li Y; Xu Q; Yang H; Lizaso A; Mao X; Jin R; Zeng Y; Li Q; Wang J; Li Y; Zhang Y; Yang N
Cancer Immunol Immunother; 2021 Sep; 70(9):2517-2528. PubMed ID: 33566148
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of anti-PD-1 monotherapy
Liu Q; Li R; Li L; Wang G; Ji S; Zheng X; Jia X; Tao H; Hu Y
Ther Adv Med Oncol; 2023; 15():17588359231206274. PubMed ID: 37885459
[TBL] [Abstract][Full Text] [Related]
4. PD-1 inhibitor combined with chemotherapy for first-line treatment of esophageal squamous cell carcinoma patients with distant metastasis: a real-world retrospective study.
Gao L; Tang L; Peng J; Hu Z; Yang J; Liu B
Front Immunol; 2024; 15():1353445. PubMed ID: 38576619
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of anlotinib plus anti-PD-1 agents in patients with refractory advanced biliary tract cancers.
An T; Hui Q; Zong H; Liu L; Cao X; Li R; Hu S; Liu Y; Li J; Zhao R
Clin Transl Oncol; 2024 Mar; ():. PubMed ID: 38530557
[TBL] [Abstract][Full Text] [Related]
6. A Retrospective Study of Anlotinib Combined with Anti-PD-1 Inhibitors in the 2nd or Later-Line Treatment of Advanced Solid Tumors.
Li SH; Li YW; Li YJ; Liu LB; Zhang Q; Lu D
Int J Gen Med; 2023; 16():4485-4498. PubMed ID: 37814643
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study.
Zhao J; Guo Y; Feng T; Rong D; Kong X; Huang T; Lopez-Lopez V; Yarmohammadi H; Sakamoto Y; Zhu D; Yao A; Xia Y
J Gastrointest Oncol; 2023 Dec; 14(6):2549-2558. PubMed ID: 38196523
[TBL] [Abstract][Full Text] [Related]
8. Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients.
Yuan S; Peng L; Liu Y; Till BG; Yan X; Zhang J; Zhu L; Wang H; Zhang S; Li H; Gao Q; Wang Z
Cancer Immunol Immunother; 2023 Feb; 72(2):437-448. PubMed ID: 35931835
[TBL] [Abstract][Full Text] [Related]
9. The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma.
Song Y; Xiao J; Fang W; Lu P; Fan Q; Shu Y; Feng J; Zhang S; Ba Y; Zhao Y; Liu Y; Bai C; Bai Y; Tang Y; He J; Huang J
Cancer Biol Med; 2021 Mar; 18(2):562-8. PubMed ID: 33724741
[TBL] [Abstract][Full Text] [Related]
10. Sintilimab plus anlotinib as second or further-line therapy for extensive disease small cell lung cancer: a phase 2 investigator-initiated non-randomized controlled trial.
Ma S; He Z; Liu Y; Wang L; Yang S; Wu Y; Chen H; Wu Y; Wang Q
EClinicalMedicine; 2024 Apr; 70():102543. PubMed ID: 38516099
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of anlotinib in Chinese patients with metastatic breast cancer: A retrospective observational study.
Liu S; Zhi W; Zhang L
J Cell Mol Med; 2023 Oct; 28(5):e18008. PubMed ID: 37891706
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study.
Dou XJ; Ma RY; Ren DW; Liu Q; Yan P
Lung Cancer (Auckl); 2024; 15():29-40. PubMed ID: 38560413
[TBL] [Abstract][Full Text] [Related]
13. Anlotinib in recurrent or metastatic endometrial cancer.
Cui Q; Mao Y; Hu Y; Ma D; Liu H
Int J Gynecol Cancer; 2022 May; ():. PubMed ID: 35606048
[TBL] [Abstract][Full Text] [Related]
14. Etoposide soft capsule combined with anlotinib in the third-line treatment of advanced non-small cell lung cancer: a retrospective cohort study.
Dai YJ; Qiu YR; Lin JG; Dai YB; Su YX; Yamada T; Uematsu S; Xu TW
J Thorac Dis; 2023 Oct; 15(10):5680-5688. PubMed ID: 37969289
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy and safety of anlotinib monotherapy or anlotinib plus immune checkpoint inhibitor for advanced small cell lung cancer with brain metastases.
Xu M; Shao K; Wang Y; Hao Y; Song Z
Clin Transl Oncol; 2024 Feb; ():. PubMed ID: 38363527
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and adverse effects of anlotinib in the treatment of high-grade glioma: A retrospective analysis.
Shen F; Li J; Liu F; Sun N; Qiu X; Ding W; Sun X
Front Oncol; 2023; 13():1095362. PubMed ID: 36874124
[TBL] [Abstract][Full Text] [Related]
17. Anti-PD-L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy-refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study.
Ning T; Li D; Deng T; Bai Y; Chen Y; Wang Z; Hu B; Ba Y; Lu W
Cancer; 2024 May; ():. PubMed ID: 38781433
[TBL] [Abstract][Full Text] [Related]
18. Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203).
Han C; Ye S; Hu C; Shen L; Qin Q; Bai Y; Yang S; Bai C; Zang A; Jiao S; Bai L
Front Oncol; 2021; 11():684867. PubMed ID: 34327136
[TBL] [Abstract][Full Text] [Related]
19. Efficacies of anlotinib monotherapy versus gemcitabine-based chemotherapy for patients with advanced soft tissue sarcoma after the failure of anthracycline-based chemotherapy.
Zheng A; Liu J; Liu Z; Mo Z; Fu Y; Deng Y; Jiang Y
J Cancer Res Clin Oncol; 2024 Jan; 150(2):58. PubMed ID: 38294686
[TBL] [Abstract][Full Text] [Related]
20. Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer.
Hu N; Si Y; Yue J; Sun T; Wang X; Jia Z; Gao S; Li Q; Shao Y; Wang J; Luo Y; Ma F; Xu B; Yuan P
Cancer Biol Med; 2021 Mar; 18(3):849-59. PubMed ID: 33710812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
